Page last updated: 2024-11-04

cystine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

L-cystine : The L-enantiomer of the sulfur-containing amino acid cystine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID67678
CHEMBL ID590540
CHEBI ID16283
SCHEMBL ID10226
MeSH IDM0005555
PubMed CID3036261
SCHEMBL ID10225
MeSH IDM0005555

Synonyms (148)

Synonym
e921
(2r,2'r)-3,3'-disulfanediylbis(2-aminopropanoic acid)
CHEBI:16283 ,
3,3'-dithiobis-l-alanine
bis(beta-amino-beta-carboxyethyl) disulfide
(r-(r*,r*))-3,3'-dithiobis(2-aminopropanoic acid)
beta,beta'-diamino-beta,beta'-dicarboxydiethyl disulfide
beta,beta'-dithiodialanine
cystine (van)
ai3-09064
einecs 200-296-3
nsc 13203
cystin (van)
brn 1728094
cystine [usan]
ccris 5822
3,3'-dithiodialanine
3,3'-dithiobis(2-aminopropanoic acid)
nsc-13203
cystine, l-
l-(-)-cystine
alanine, 3,3'-dithiobis-
l-cystine (jp17)
cystine (usan/inn)
D03636
gelucystine
cystine, l- (8ci)
l-alanine, 3,3'-dithiobis-
3,3'-dithiobis(2-aminopropanoic acid), (r-(r*,r*))-
cystine (l)-
2-amino-3-(2-amino-2-carboxy-ethyl)disulfanyl-propanoic acid
alanine, 3,3'-dithiodi-
l-cysteine disulfide
beta,beta'-diamino-beta,beta'-dicarboxydiethyldisulfide
l-cystin
1-cystine
l-cystine (9ci)
bis(beta-amino-beta-carboxyethyl)disulfide
beta,beta'-dithioalanine, l-
propanoic acid, 3,3'-dithiobis(2-amino-, (r-(r*,r*))-
56-89-3
l-cystine
C00491
l-dicysteine
l-alpha-diamino-beta-dithiolactic acid
l-cystine, from non-animal source, meets ep testing specifications, suitable for cell culture, 98.5-101.0%
l-cystine, >=98% (tlc), crystalline
(r,r)-3,3'-dithiobis(2-aminopropanoic acid)
DB00138
NCGC00166006-01
l-cystine, bioultra, >=99.5% (t)
AC-11189
DD82F461-3F8F-4624-9E2C-0272A9FA79ED
(h-cys-oh)2
cystine,d
BMSE000035
CHEMBL590540
l cystine
cas-56-89-3
dtxcid0026418
dtxsid2046418 ,
tox21_112162
c6h12n2o4s2
CCG-36355
48tcx9a1vt ,
ec 200-296-3
cystine [usan:inn]
unii-48tcx9a1vt
4-04-00-03155 (beilstein handbook reference)
cystine [usp-rs]
cystine [mi]
l-cystine [fcc]
cystine [inci]
cystine [inn]
l-cystine [jan]
tyrosine impurity c [ep impurity]
3,3-disulfanediylbis((2r)-2-aminopropanoic acid)
cystine [ep monograph]
cystine [who-dd]
s-cysteinyl cysteine
cystine [mart.]
acetylcysteine impurity a [ep impurity]
cystine [vandf]
AKOS015898645
S4808
(2r)-2-amino-3-{[(2r)-2-amino-2-carboxyethyl]disulfanyl}propanoic acid
gtpl5413
AM81644
SCHEMBL10226
NCGC00166006-02
tox21_112162_1
(2r)-2-amino-3-[[(2r)-2-amino-2-carboxy-ethyl]disulfanyl]propanoic acid
3,3'-dithiobis
l-cystine, cell culture reagent (h-l-cys(1)-oh.h-l-cys(1)-oh)
cystine, european pharmacopoeia (ep) reference standard
l-cystine, produced by wacker chemie ag, burghausen, germany, >=98.5%
(r,r)-3,3'-dithiobis(2-aminopropionicacid)
M06021
l-cystine, saj special grade, >=99.0%
l-cystine, certified reference material, tracecert(r)
l-cystine, >=99.7% (tlc)
cystine, united states pharmacopeia (usp) reference standard
l-cystine, non-animal source
l-cystine, pharmaceutical secondary standard; certified reference material
cystine, nist(r) srm(r) 143d
l-cystine, vetec(tm) reagent grade, 98%
[r-(r*,r*)]-3,3'-dithiobis
d(+)-3,3'-dithiobis(2-aminopropanoic acid
bis(b-amino-beta-carboxyethyl) disulfide
(r-(r*,r*))-3,3'-dithiobis
3,3'-dithiobis[2-amino-[r-(r*,r*)]-propanoate
2-amino-3-(2-amino-2-carboxy-ethyl)disulfanyl-propanoate
3,3'-dithiobis[2-amino-[r-(r*,r*)]-propanoic acid
2-amino-3-[(2-amino-2-carboxyethyl)dithio]propanoic acid
beta,beta'-dithiobisalanine
2-amino-3-[(2-amino-2-carboxyethyl)dithio]propanoate
d(+)-3,3'-dithiobis(2-aminopropanoate
bis(b-amino-b-carboxyethyl) disulfide
b,b'-dithiodialanine
b,b'-diamino-b,b'-dicarboxydiethyl disulfide
HY-N0394
CS-0008930
(2r)-2-azanyl-3-[[(2r)-2-azanyl-3-oxidanyl-3-oxidanylidene-propyl]disulfanyl]propanoic acid
Q408626
s-(((r)-2-amino-2-carboxyethyl)thio)cysteine
2079930-29-1
AS-12654
acetylcysteine impurity a (l-cystine)
(h-cys-oh)2 (disulfide bond)
IYY ,
EN300-174654
[r-(r*,r*)]-3,3'-dithiobis[2-aminopropanoic acid]
Z1269145231
3,3'-disulfanediylbis((2r)-2-aminopropanoic acid)
acetylcysteine impurity a (ep impurity)
dtxcid60210087
cystine (mart.)
cystine (ep monograph)
cystinum
cystine (usp-rs)
tyrosine impurity c (ep impurity)
inchi=1/c6h12n2o4s2/c7-3(5(9)10)1-13-14-2-4(8)6(11)12/h3-4h,1-2,7-8h2,(h,9,10)(h,11,12)/t3-,4?/m0/s
cystine ,
AKOS015897282
SCHEMBL10225
DS-14359
l-cystine, 99%
2-amino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]propanoic acid

Research Excerpts

Toxicity

The toxic potencies of glutamate, quisqualate, and homocysteate were inversely proportional to the concentration of cystine in the medium. Methylseleninic acid, l-selenocystine, selenodiglutathione or selenite induced cell death in micromolar concentrations.

ExcerptReferenceRelevance
" The resulting dose-response curves obtained with CHO/DEM and control CHO cells indicated that chronic exposure to DEM, which resulted in chronic elevation of glutathione, did not provide protection against any of the three toxic treatments."( Failure of chronic glutathione elevation to reduce cytotoxicity produced by exposure to cis-diamminedichloroplatinum(II), ionizing radiation, or hyperthermia.
Eisert, DR; Freeman, ML; Meredith, MJ, 1990
)
0.28
" The toxic potencies of glutamate, quisqualate, and homocysteate were inversely proportional to the concentration of cystine in the medium, suggesting that they competitively inhibit cystine uptake."( Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake.
Coyle, JT; Murphy, TH; Schnaar, RL, 1990
)
0.28
"05% taurine in addition to an excess of cystine, four cats died after showing minimal symptoms of lethargy and unsteadiness and the remainder showed no adverse effects."( Cystine neurotoxicity is increased by taurine deficiency.
Gargano, AD; Imaki, H; Messing, JM; Rerecich, M; Rudelli, R; Sturman, JA, 1989
)
0.28
" Basic amino acids (except histidine) were less effective in protecting embryos: Glutamine and lysine reduced the toxic effect only slightly, and arginine had no effect."( Enhancement of methylmercury toxicity by L-cystine in cultured mouse blastocysts.
Matsumoto, N; Spindle, A,
)
0.13
" Among related amino acids, DL-alpha-aminoadipic acid (DL-alpha-AAA), which is well known as a selective gliotoxin in the retina, is also toxic to these cells."( Cystine/glutamate antiporter expression in retinal Müller glial cells: implications for DL-alpha-aminoadipate toxicity.
Ishita, S; Kato, S; Mawatari, K; Sugawara, K, 1993
)
0.29
" Thus, toxic selective media enriched a resistant population."( Evaluation of the toxicity of Salmonella selective media for shortening the enrichment period.
Chen, H; Fraser, AD; Yamazaki, H, 1993
)
0.29
" The data suggested that cisplatin is an important toxic drug for olfactory system."( [The olfactory neurotoxicity of cisplatin and effects of two drugs].
Lin, S; Zhou, G, 1995
)
0.29
" Accumulation of the hydrogen selenide resulting from inhibition of the selenium methylation metabolism, detoxification metabolic pathway of selenium, is found in animals following repeated administration of a toxic dose of selenocystine."( [Selenium methylation and toxicity mechanism of selenocystine].
Hasegawa, T; Nakamuro, K; Sayato, Y, 1997
)
0.3
" Liver regeneration is a vital process for survival after a toxic insult, it occurs at a relative late time point after the injurious phase."( Prolonged treatment with N-acetylcystine delays liver recovery from acetaminophen hepatotoxicity.
Fink, MP; He, X; Killeen, ME; Miki, K; Yang, R, 2009
)
0.35
"In epilepsy, traumatic brain injury, and ischemic stroke, toxic levels of zinc released from neurons contribute to the brain damage associated with these disorders."( Histidine, cystine, glutamine, and threonine collectively protect astrocytes from the toxicity of zinc.
Bishop, GM; Campbell, MS; Ralph, DM; Robinson, SR, 2010
)
0.36
" Methylseleninic acid, l-selenocystine, selenodiglutathione or selenite induced cell death in micromolar concentrations, whereas selenomethionine or ebselen was not toxic within the concentration range tested."( Comparison of different selenocompounds with respect to nutritional value vs. toxicity using liver cells in culture.
Birringer, M; Hoefig, CS; Köhrle, J; Renko, K; Schomburg, L, 2011
)
0.37
"Constructing safe and effective gene delivery carriers is becoming highly desirable for gene therapy."( Recycling gene carrier with high efficiency and low toxicity mediated by L-cystine-bridged bis(β-cyclodextrin)s.
Chen, JT; Chen, Y; Liu, Y; Yang, Y; Zhang, YH; Zhang, YM, 2014
)
0.4
"Nutritional therapy is used to reduce the adverse events (AEs) of anticancer drugs."( Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients.
Hashimoto, T; Honda, H; Kakita, T; Kayahara, T; Kurihara, S; Oikawa, M; Oishi, H; Oyama, A; Shibakusa, T; Tochikubo, K; Tsuchiya, T, 2016
)
0.43
"Methyl mercury (MeHg) is a highly toxic substance and the effect of selenium against MeHg toxicity is a hot topic."( Selenocystine against methyl mercury cytotoxicity in HepG2 cells.
Chen, B; He, M; Hu, B; Wang, H; Yu, X, 2017
)
0.46
" These rankings correlate with in vivo data and demonstrate successful application of the assay to rank a series of related toxic and non-toxic compounds."( A human induced pluripotent stem cell-based in vitro assay predicts developmental toxicity through a retinoic acid receptor-mediated pathway for a series of related retinoid analogues.
Burrier, RE; Colwell, MR; Donley, ELR; Egnash, LA; Kirchner, FR; Palmer, JA; Smith, AM, 2017
)
0.46
" Role of Asp 110 in GCSF as the critical residue having adverse impact on efficacy in context of methionine oxidation has been elucidated."( Understanding Oxidation Propensity in GCSF and Assessment of its Safety and Efficacy.
Kumar, D; Rathore, AS; Singh, SK, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
"027 min-1 corresponding to a half-life of 14."( High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine.
Aebi, S; Assereto, R; Lauterburg, BH, 1991
)
0.28
" The plasma concentrations were determined by pre-column derivatization HPLC-FL method and the pharmacokinetic parameters of fudosteine were calculated."( [Pharmacokinetics of fudosteine in healthy volunteers].
Ding, L; Li, RS; Shen, JP; Yang, J; Zhang, YD; Zhou, M, 2005
)
0.33
"The obtained pharmacokinetic parameters of fudosteine in single dose of 600 mg, 400 mg and 200 mg groups were as follows: T1/2 were (2."( [Pharmacokinetics of fudosteine in healthy volunteers].
Ding, L; Li, RS; Shen, JP; Yang, J; Zhang, YD; Zhou, M, 2005
)
0.33
"The values of pharmacokinetic parameters in healthy volunteers were linear in the range from 200 mg to 600 mg."( [Pharmacokinetics of fudosteine in healthy volunteers].
Ding, L; Li, RS; Shen, JP; Yang, J; Zhang, YD; Zhou, M, 2005
)
0.33
" Plasma pharmacokinetic parameters were calculated by using a two-compartment model."( Pharmacokinetics, biodistribution and contrast enhanced MR blood pool imaging of Gd-DTPA cystine copolymers and Gd-DTPA cystine diethyl ester copolymers in a rat model.
Feng, Y; Jeong, EK; Ke, T; Lu, ZR; Parker, DL; Zong, Y, 2006
)
0.33
" Noncompartmental analysis was used for the calculation of the total area under the plasma concentration-time curve (AUC) from time zero to time infinity and the terminal half-life (t1/2) of fudosteine."( The pharmacokinetics of orally administered fudosteine in healthy Chinese volunteers.
Chen, Y; Jiao, HY; Tian, Y; Xu, FG; Zhang, BB; Zhang, ZJ,
)
0.13
" Using the maximally tolerated dose of imexon, we sought to identify a potential pharmacodynamic biomarker to monitor the mechanistic effect systemically."( Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice.
Dorr, RT; Hersh, E; Kepler, CY; Meyers, RO; Pourpak, A; Raymond, MA; Samulitis, BK; Sherry Chow, HH, 2006
)
0.33
" Pharmacokinetic data were analyzed by means of an open two-compartment model."( Modification of Gd-DTPA cystine copolymers with PEG-1000 optimizes pharmacokinetics and tissue retention for magnetic resonance angiography.
Emerson, L; Feng, Y; Jeong, EK; Lu, ZR; Mohs, AM; Nguyen, T; Parker, DL; Zong, Y, 2007
)
0.34
" A total of 250 cysteamine plasma concentrations and 243 intracellular cystine concentrations were used to perform a population pharmacokinetic and pharmacodynamic analysis."( Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
Bouazza, N; Chadefaux-Vekemans, B; Deschenes, G; Niaudet, P; Ottolenghi, C; Ricquier, D; Tréluyer, JM; Urien, S, 2011
)
0.37
"This study investigates the pharmacokinetic characteristics after intravenous administration of Sudaxine by using a simple liquid chromatography-tandem mass spectrometry (LC-MS/MS) method."( Pharmacokinetic study of Sudaxine in dog plasma using novel LC-MS/MS method.
Altawallbeh, G; Authier, S; Bederman, I; Bujold, K; Gaston, B; Lewis, SJ; Smith, L, 2019
)
0.51
" Blood samples (1 mL) were collected at designated time points and SDX concentration was measured for pharmacokinetic study."( Pharmacokinetic study of Sudaxine in dog plasma using novel LC-MS/MS method.
Altawallbeh, G; Authier, S; Bederman, I; Bujold, K; Gaston, B; Lewis, SJ; Smith, L, 2019
)
0.51
"We developed a novel LC-MS/MS method of Sudaxine detection and quantification and determined its pharmacokinetic profiles after intravenous administration in canine subjects."( Pharmacokinetic study of Sudaxine in dog plasma using novel LC-MS/MS method.
Altawallbeh, G; Authier, S; Bederman, I; Bujold, K; Gaston, B; Lewis, SJ; Smith, L, 2019
)
0.51
" To understand the implications of dose and species differences, a physiologically based pharmacokinetic model (PBPK) for DBC and major metabolites was developed in mice and humans."( Translating dosimetry of Dibenzo[def,p]chrysene (DBC) and metabolites across dose and species using physiologically based pharmacokinetic (PBPK) modeling.
Corley, RA; Crowell, SR; Madeen, EP; Ognibene, TJ; Pande, P; Smith, JN; Turteltaub, KW; Williams, DE, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" The total concentration of FT in the plasma and the tumor when it was given in combination with L-cystine was significantly increased when compared with FT alone 1 h after oral administration."( Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine.
Hoshi, A; Iigo, M; Kitagawa, H, 1986
)
0.27
"The cyclization of linear analogs based on endomorphin-2 structure, Tyr/Dmt-d-Lys-Phe-Phe-Asp-NH2 and Tyr/Dmt-d-Cys-Phe-Phe-Cys-NH2 (where Dmt=2',6'-dimethyltyrosine), resulting in obtaining lactam or disulfide derivatives, was studied using liquid chromatography combined with on-line mass spectrometry (LC-MS) and tandem mass spectrometry (LC-MS/MS)."( Cyclic pentapeptide analogs based on endomorphin-2 structure: cyclization studies using liquid chromatography combined with on-line mass spectrometry and tandem mass spectrometry.
Janecka, A; Kluczyk, A; Perlikowska, R; Piekielna, J, 2014
)
0.4

Bioavailability

The triple-lumen perfusion method was used to measure the rate of absorption of trace quantities of selenium from the jejunum. We evaluated the effects of administration route and dose on the bioavailability of nine Se compounds.

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Results from the application of this method to a bioavailability study in humans are given."( Determination of carbocysteine from human plasma.
Bruce, RB; Fox, GG; Maynard, WR, 1978
)
0.26
" In this study, the triple-lumen perfusion method was used to measure the rate of absorption of trace quantities of selenium (50 micrograms/liter in a physiological electrolyte solution) from the jejunum when given as D,L-selenomethione, D,L-selenocystine, or sodium selenite to healthy dogs in vivo."( Selenium absorption by canine jejunum.
Barbezat, GO; Reasbeck, PG; Robinson, MF; Thomson, CD; Weber, FL, 1985
)
0.27
"Various aspects of selenium metabolism and nutrition in relation to the question of selenium bioavailability in foods and the diet of man are reviewed."( Selenium bioavailability with reference to human nutrition.
Janghorbani, M; Nahapetian, A; Young, VR, 1982
)
0.26
"The digestibility and bioavailability of amino acids (AA) in meat and bone meals (MBM) may vary greatly due to different processing conditions."( Dietary formulation with meat and bone meal on a total versus a digestible or bioavailable amino acid basis.
Parsons, CM; Wang, X, 1998
)
0.3
" Relative oral bioavailability (RBV) values, with the L-isomer of Met and Cys set at 100% (isosulfurous basis), are near 100% for D-Met for animals but only about 30% for humans."( Comparative species utilization and toxicity of sulfur amino acids.
Baker, DH, 2006
)
0.33
"5h and excellent oral bioavailability of 73%."( A-366833: a novel nicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane alpha4beta2 nicotinic acetylcholine receptor selective agonist: Synthesis, analgesic efficacy and tolerability profile in animal models.
Ahring, PK; Anderson, DJ; Buckley, MJ; Bunnelle, WH; Curzon, P; Dyhring, T; Faltynek, C; Ji, J; Kempf-Grote, A; Marsh, KC; Meyer, MD; Rueter, LE, 2007
)
0.34
"The objective of the present study was to describe the uptake and elimination kinetics of selenium (Se) administered in the forms of selenate, selenite, and selenomethionine (seleno-DL-methionine) in different life stages of the midge Chironomus dilutus, and to determine the relationship between Se bioavailability and Se speciation using X-ray absorption spectroscopy (XAS)."( Selenium bioaccumulation and speciation in Chironomus dilutus exposed to water-borne selenate, selenite, or seleno-DL-methionine.
Franz, ED; Janz, DM; Liber, K; Pickering, IJ; Wiramanaden, CI, 2011
)
0.37
"In vitro bioavailability of total selenium and selenium species from different raw seafood has been assessed by using a simulated gastric and intestinal digestion/dialysis method."( In vitro bioavailability of total selenium and selenium species from seafood.
Alonso-Rodríguez, E; Bermejo-Barrera, P; Domínguez-González, R; López-Mahía, P; Moreda-Piñeiro, A; Moreda-Piñeiro, J; Muniategui-Lorenzo, S; Prada-Rodríguez, D; Romarís-Hortas, V, 2013
)
0.39
"As mercury (Hg) biosensors are sensitive to only intracellular Hg, they are useful in the investigation of Hg uptake mechanisms and the effects of speciation on Hg bioavailability to microbes."( The Use of a Mercury Biosensor to Evaluate the Bioavailability of Mercury-Thiol Complexes and Mechanisms of Mercury Uptake in Bacteria.
Al-Farawati, R; Barkay, T; Liu, J; Mason, RP; Ndu, U; Reinfelder, JR; Traore Schartup, A, 2015
)
0.42
" We evaluated the effects of administration route and dose on the bioavailability of nine Se compounds found in biota, the so-called bioselenocompounds, such as selenite, selenate, selenocyanate (SeCN), Se-methylselenocysteine (MeSeCys), selenomethionine (SeMet), selenohomolanthionine (SeHLan), selenocystine (SeCys2), 1β-methylseleno-N-acetyl-d-galactosamine (SeSug1), and trimethylselenonium ion (TMSe)."( Effect of administration route and dose on metabolism of nine bioselenocompounds.
Ogra, Y; Suzuki, N; Takahashi, K, 2018
)
0.48
" Hence, the improvement in solubility and bioavailability of ACF is very crucial for successful product development."( Novel Aceclofenac-l-Cystine and Aceclofenac-Urea Cocrystals with Enhanced Oral Bioavailability.
Gupta, A; Kumar, S; Mishra, CK; Singh, S, 2021
)
0.62
"The specific objective of this research work was the measurement of bioavailability and other pharmacokinetic parameters of ACF cocrystals prepared by the mechanochemical grinding method."( Novel Aceclofenac-l-Cystine and Aceclofenac-Urea Cocrystals with Enhanced Oral Bioavailability.
Gupta, A; Kumar, S; Mishra, CK; Singh, S, 2021
)
0.62
"Cocrystals of ACF with l-cystine and urea were prepared by neat grinding (NG) method and in-vivo oral bioavailability of prepared cocrystals was measured in Wistar rats."( Novel Aceclofenac-l-Cystine and Aceclofenac-Urea Cocrystals with Enhanced Oral Bioavailability.
Gupta, A; Kumar, S; Mishra, CK; Singh, S, 2021
)
0.62
"Percent relative bioavailability of ACF-l-CYS NG and ACF-UREA NG cocrystals in Wistar rats was found to be 242."( Novel Aceclofenac-l-Cystine and Aceclofenac-Urea Cocrystals with Enhanced Oral Bioavailability.
Gupta, A; Kumar, S; Mishra, CK; Singh, S, 2021
)
0.62
"The present study indicates that the enhanced aqueous solubility of the prepared cocrystals leads to enhanced oral bioavailability of ACF."( Novel Aceclofenac-l-Cystine and Aceclofenac-Urea Cocrystals with Enhanced Oral Bioavailability.
Gupta, A; Kumar, S; Mishra, CK; Singh, S, 2021
)
0.62

Dosage Studied

The dosage of 50 mg/kg/day is effective as judged by the leucocyte cystine content, even if given in only three doses per day. DR-cysteamine should be dosed higher than 70% of the equivalent dose of IR-cy Steine. Even though Cys and its oxidized product (cystine) are equally efficacious at levels at or below their dietary requirements for maximal growth, Cys is far more toxic than Cy.

ExcerptRelevanceReference
" In addition, our preparation did not demonstrate the long-lasting responses to bromoaTT-induced depression of the nicotinic responses was studied on the dose-response curves; the mode of receptor inhibition was rather complexed, being neither type of competitive nor non-competitive."( Effects of disulfide bond reduction on the excitatory and inhibitory postsynaptic responses of Aplysia ganglion cells.
Sato, M; Sato, T; Sawada, M, 1976
)
0.26
" Its indications in the therapy of RA were defined, and current principles of dosage were presented."( Penicillamine in rheumatoid arthritis: clinical pharmacology and biochemical properties.
Jaffe, IA, 1979
)
0.26
" This sensitive and specific assay helped in controlling compliance and adjusting dosage regimen in each patient."( [Intra-leukocyte cystine in cystinosis treated with cysteamine].
Broyer, M; Ged, C; Jean, G; Kamoun, P; Tete, MJ, 1991
)
0.28
" The resulting dose-response curves obtained with CHO/DEM and control CHO cells indicated that chronic exposure to DEM, which resulted in chronic elevation of glutathione, did not provide protection against any of the three toxic treatments."( Failure of chronic glutathione elevation to reduce cytotoxicity produced by exposure to cis-diamminedichloroplatinum(II), ionizing radiation, or hyperthermia.
Eisert, DR; Freeman, ML; Meredith, MJ, 1990
)
0.28
" with 950 mg/kg of OTC 4 hours before dosing with 5-FU."( Effects of L-2-oxothiazolidine-4-carboxylate, a cysteine pro-drug, on teratogenicity of 5-fluorouracil in mice.
Deguchi, T; Mataki, Y; Naya, M; Noguchi, M; Yasuda, M, 1990
)
0.28
" In conclusion, the effectiveness of cysteamine seems obvious in this group of patients if rigorous compliance with the drug dosing schedule is achieved."( [Treatment of cystinosis using cysteamine].
Broyer, M; Tete, MJ, 1990
)
0.28
"A material of 110 consecutive patients submitted to elective upper abdominal laparotomy participated in a randomized double-blind investigation of the effect of N-acetylcysteine (Mucomyst) administered systemically in the recommended dosage on postoperative expectoration."( [The effect of systemic N-acetylcysteine on postoperative expectoration. A prospective, randomized double-blind study].
Jepsen, S; Johansen, K; Klaerke, A; Nielsen, PH, 1989
)
0.28
" The daily dosage was 18,000 IE retinol, 70 mg L-cystine and 7000 mg gelatin."( [Low dosage retinol and L-cystine combination improve alopecia of the diffuse type following long-term oral administration].
Baumann, I; Gollnick, H; Hertel, H; Matthies, C; Orfanos, CE, 1989
)
0.28
"Chronic dosing of rats with isoniazid (INH) leads to an increase in the incidence of short "spontaneous" sprouts on motor end plates in the rat sternocostalis muscle."( The effects of chronic isoniazid intoxication on motor end plate sprouting in rat sternocostalis muscle and on responses to partial denervation and local botulinum toxin.
Cavanagh, JB; Kemplay, S, 1984
)
0.27
" Among three dosage regimens, the dosage of 50 mg/kg/day is effective as judged by the leucocyte cystine content, even if given in only three doses per day."( Treatment of cystinosis with cysteamine. A pilot study determining dose and form of application.
Bergonzi, E; Bühlmann, C; Herren, A; Lavanchy, P; Lüthy, C; Oetliker, O; Wyss, SR, 1981
)
0.26
" The addition of 10(-5) M 2-ME to cystine shifted the dose-response curve to lower concentrations by about one order of magnitude."( A mechanism of the augmentation of antibody response in vitro by 2-mercaptoethanol: facilitation of cystine uptake in murine lymphocytes.
Ohmori, H; Yamamoto, I, 1982
)
0.26
" Based on dose-response curves from two broiler experiments, the model calculates additional income from improved feed conversion and from increased breast meat yield."( Sulfur amino acid requirement of broiler chicks from fourteen to thirty-eight days of age. 2. Economic evaluation.
Pack, M; Schutte, JB, 1995
)
0.29
" Animals were dosed 6 days/week for 30, 60 or 90 days with 0, 5, 10 or 15 mg/kg per day."( Toxicity and chemical form of selenium in the liver of mice orally administered selenocystine for 90 days.
Hasegawa, T; Mihara, M; Nakamuro, K; Sayato, Y; Taniguchi, S, 1994
)
0.29
"A 6-day course of intravenous N-acetylcysteine at the dosage used does not prevent BPD or death in infants with extremely low birth weight."( N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial.
Ahola, T; Esberg, G; Fellman, V; Jonsbo, F; Jonsson, B; Kjartansson, S; Lapatto, R; Lossius, K; Raivio, KO; Selander, B; Stigson, L; Stiris, T; Stövring, S; Virkola, K, 2003
)
0.32
" Even though Cys and its oxidized product (cystine) are equally efficacious at levels at or below their dietary requirements for maximal growth, Cys is far more toxic than cystine when administered orally in the pharmacologic dosing range."( Comparative species utilization and toxicity of sulfur amino acids.
Baker, DH, 2006
)
0.33
" The maximally tolerated dose, at the selected dosing schedule, was 150 mg/kg."( Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice.
Dorr, RT; Hersh, E; Kepler, CY; Meyers, RO; Pourpak, A; Raymond, MA; Samulitis, BK; Sherry Chow, HH, 2006
)
0.33
" Drug dosage was adjusted to maintain free urine cystine level below 100 micromol/mmol creatinine."( Cystinuria in children and young adults: success of monitoring free-cystine urine levels.
Dello Strologo, L; Laurenzi, C; Legato, A; Pastore, A, 2007
)
0.34
" Cystagon efficacy requires strict lifelong dosing every 6 hours."( A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.
Bagger, MJ; Cochat, P; Cornelissen, E; Deschênes, G; Gaillard, S; Greenbaum, LA; Grimm, P; Langman, CB; Matossian, D; Morin, D; Niaudet, P; Rioux, P; Sarwal, M, 2012
)
0.38
" In the present study, the toxicity of 4 compounds (selenate, selenite, methylselenocysteine, and selenocystine) to honeybee adult foragers and larvae was assessed using dose-response bioassays."( Effects of selenium on development, survival, and accumulation in the honeybee (Apis mellifera L.).
Hladun, KR; Kaftanoglu, O; Parker, DR; Tran, KD; Trumble, JT, 2013
)
0.39
" Relation of these complications to age, renal functions and the dosage of cysteamine were studied."( Long-term endocrinologic complications of cystinosis.
Besbas, N; Bilginer, Y; Gultekingil Keser, A; Topaloglu, R, 2014
)
0.4
"Radioresistance and limitation of irradiative dosage usually lead to failure in depletion of hypoxic tumors."( Dual-function nanosystem for synergetic cancer chemo-/radiotherapy through ROS-mediated signaling pathways.
Chen, T; He, L; Lai, H, 2015
)
0.42
" The established cysteamine formulation requires a strict dosing regimen at 6-h intervals."( Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
Ahlenstiel-Grunow, T; Drube, J; Froede, K; Kanzelmeyer, NK; Kreuzer, M; Lerch, C; Pape, L, 2017
)
0.46
"Appropriate dosing of cystine-binding thiol drugs in the management of cystinuria has been based on clinical stone activity."( Effect of increasing doses of cystine-binding thiol drugs on cystine capacity in patients with cystinuria.
Asplin, JR; Enders, FT; Goldfarb, DS; Malieckal, DA; Mara, K; Modersitzki, F, 2019
)
0.51
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."(
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022
)
0.72
" Our data show that DR-cysteamine should be dosed higher than 70% of the equivalent dose of IR-cysteamine in order to decrease cystine levels over an extended period of time."( A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis.
Grebe, J; Grüneberg, M; Harms, E; Klank, S; Marquardt, T; Ottolenghi, C; Reunert, J; van Stein, C, 2021
)
0.62
" PBPK model simulations were evaluated against mice dosed with 15 mg/kg DBC by oral gavage and human volunteers orally microdosed with 29 ng of DBC."( Translating dosimetry of Dibenzo[def,p]chrysene (DBC) and metabolites across dose and species using physiologically based pharmacokinetic (PBPK) modeling.
Corley, RA; Crowell, SR; Madeen, EP; Ognibene, TJ; Pande, P; Smith, JN; Turteltaub, KW; Williams, DE, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
flour treatment agentA food additive which is added to flour or dough to improve baking quality and/or colour.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
EC 1.2.1.11 (aspartate-semialdehyde dehydrogenase) inhibitorAny EC 1.2.1.* (oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor) inhibitor that inhibits the action of aspartate-semialdehyde dehydrogenase (EC 1.2.1.11).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
cystineA sulfur-containing amino acid obtained by the oxidation of two cysteine molecules which are then linked via a disulfide bond.
L-cysteine derivativeA proteinogenic amino acid derivative resulting from the formal reaction of L-cysteine at the amino group, carboxy group, or thiol group, or from the replacement of any hydrogen of L-cysteine by a heteroatom.
non-proteinogenic L-alpha-amino acidAny L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
cystine zwitterionAn amino acid zwitterion that is the tautomer of cystine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (8)

PathwayProteinsCompounds
Transport of small molecules39295
SLC-mediated transmembrane transport13567
Transport of inorganic cations/anions and amino acids/oligopeptides5427
Miscellaneous transport and binding events184
Methionine and Cysteine metabolism ( Methionine and Cysteine metabolism )2342
Oxidative stress and redox pathway019
AtMetExpress overview0109
Biochemical pathways: part I0466

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency0.30113.189029.884159.4836AID1224846
GLI family zinc finger 3Homo sapiens (human)Potency0.26720.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency0.00240.000221.22318,912.5098AID743042
progesterone receptorHomo sapiens (human)Potency0.33490.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.22310.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.30110.000817.505159.3239AID1159527; AID1159531
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.37580.001024.504861.6448AID743215
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.301119.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency0.30110.057821.109761.2679AID1159526
Histone H2A.xCricetulus griseus (Chinese hamster)Potency0.61930.039147.5451146.8240AID1224845; AID1224896
heat shock protein beta-1Homo sapiens (human)Potency0.25630.042027.378961.6448AID743210; AID743228
DNA polymerase kappa isoform 1Homo sapiens (human)Potency29.93490.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID695877Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695851Resistance index, ratio of IC50 for human KB-3-1 cells to IC50 for drug-resistant human KBV1 cells expressing P-gp2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID695876Cytotoxicity against drug-resistant human KBV1 cells expressing P-gp incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,210)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903350 (53.95)18.7374
1990's853 (13.74)18.2507
2000's831 (13.38)29.6817
2010's815 (13.12)24.3611
2020's361 (5.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials97 (1.51%)5.53%
Reviews0 (0.00%)6.00%
Reviews348 (5.41%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies222 (3.45%)4.05%
Observational0 (0.00%)0.25%
Observational5 (0.08%)0.25%
Other10 (100.00%)84.16%
Other5,759 (89.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]